To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of ...

aDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA bDivision of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA cDivision of ...

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...

The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

Swapping in sacituzumab govitecan for chemotherapy led to a 3.4-month improvement in PFS and an almost twofold longer duration of response, with potentially fewer adverse events and a lower rate ...

A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned adjuvant chemotherapy based on molecular risk exhibited a 78% reduction in risk for ...

HARMONi is a multiregional, double-blinded, placebo-controlled, Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum ...

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting. Updated data from the phase 3 BREAKWATER trial ...

CHICAGO -- First-line treatment with encorafenib (Braftovi) and cetuximab (Erbitux) plus chemotherapy significantly improved survival outcomes compared with standard of care in patients with BRAF ...

Nexus Pharmaceuticals announced that on May 9, 2025, it won a patent litigation involving injectable cyclophosphamide. Cyclophosphamide has been approved for certain kinds of cancer, and Nexus had ...